Bevacizumab Intra-Articular
Synovitis
Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Taiwan University Hospital
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02060305CT.gov Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Synovitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bevacizumab Intra-Articular (this asset) | National Taiwan University Hospital | P1 | CC · 43 |
| Efanesoctocog Alfa | Swedish Orphan Biovitrum | P4 | BB |
| Capsaicin | Express Specialty Pharmacy | Unk | D |
| Marcaine | Express Specialty Pharmacy | Unk | D |
| Lidocaine | Express Specialty Pharmacy | Unk | D |
| Diclofenac | Express Specialty Pharmacy | Unk | D |
| Prilocaine | Express Specialty Pharmacy | Unk | D |
| Menthol | Express Specialty Pharmacy | Unk | D |
| Topiramate | Express Specialty Pharmacy | Unk | D |
+8 more in the Synovitis cohort
Other indications for Bevacizumab Intra-Articular
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Bevacizumab Intra-Articular in Synovitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/bevacizumab-intra-articular-synovitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →